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Russo RC, Savino B, Mirolo M, Buracchi C, Germano G,
Anselmo A, Zammataro L, Pasqualini F, Mantovani A, Locati M,
Teixeira MM. The atypical chemokine receptor ACKR2 drives pul-
monary fibrosis by tuning influx of CCR2 and CCR5 IFN-
producing T cells in mice. Am J Physiol Lung Cell Mol Physiol
314: L1010–L1025, 2018. First published February 22, 2018; doi:
10.1152/ajplung.00233.2017.— Chemokines coordinate lung inflam-
mation and fibrosis by acting on chemokine receptors expressed on
leukocytes and other cell types. Atypical chemokine receptors
(ACKRs) bind, internalize, and degrade chemokines, tuning homeo-
stasis and immune responses. ACKR2 recognizes and decreases the
levels of inflammatory CC chemokines. The role of ACKR2 in
fibrogenesis is unknown. The purpose of the study was to investigate
the role of ACKR2 in the context of pulmonary fibrosis. The effects
of ACKR2 expression and deficiency during inflammation and fibro-
sis were analyzed using a bleomycin-model of fibrosis, ACKR2-
deficient mice, bone marrow chimeras, and antibody-mediated leuko-
cyte depletion. ACKR2 was upregulated acutely in response to bleo-
mycin and normalized over time. ACKR2/ mice showed reduced
lethality and lung fibrosis. Bone marrow chimeras showed that lethal-
ity and fibrosis depended on ACKR2 expression in pulmonary resi-
dent (nonhematopoietic) cells but not on leukocytes. ACKR2/ mice
exhibited decreased expression of tissue-remodeling genes, reduced
leukocyte influx, pulmonary injury, and dysfunction. ACKR2/
mice had early increased levels of CCL5, CCL12, CCL17, and IFN
and an increased number of CCR2 and CCR5 IFN-producing T
cells in the airways counterbalanced by low Th17-lymphocyte influx.
There was reduced accumulation of IFN-producing T cells in
CCR2/ and CCR5/ mice. Moreover, depletion of T cells
worsened the clinical symptoms induced by bleomycin and reversed
the phenotype of ACKR2/ mice exposed to bleomycin. ACKR2
controls the CC chemokine expression that drives the influx of
CCR2 and CCR5 IFN-producing T cells, tuning the Th17
response that mediated pulmonary fibrosis triggered by bleomycin
instillation.
ACKR2; chemokine; interferon-; pulmonary fibrosis; T lympho-
cytes
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic lethal dis-
order characterized by an aberrant immune system and fibro-
blast activation, excessive extracellular matrix deposition, and
irreversible fibrotic changes (58). It is unclear how the early
inflammatory phases result in the later fibrotic stage that leads
to damage and progressive architectural remodeling (2, 3).
However, the involvement of inflammatory processes preced-
ing this late damage suggests that understanding the molecular
orchestration of inflammation in IPF could be useful for the
development of novel therapeutic interventions (8, 58).
During inflammatory reactions, chemokines are induced
following tissue damage or infection (54) and coordinate the
recruitment and activation of leukocytes and other cell types
(25). As such, chemokines have a role in the pathogenesis of
several diseases (47, 48, 51, 58). In the context of IPF and
animal models of fibrosis, chemokines and their receptors,
including CCR2/CCL2 (30, 61), CCR5/CCL3 (14, 38, 49),
CCR3/CCL11 (13), and CXCR2/CXCL1–3 (18, 41), have
been implicated in initiating the inflammatory phase and in the
perpetuation of inappropriate fibroblast activity. Chemokine
signals lead to cell activation and recruitment through their
specific receptors. A small family of atypical chemokine re-
ceptors (ACKRs) (1) bind to chemokines, do not activate the
conventional signaling cascades leading to cell chemotaxis, but
trigger pathways of chemokine transport or degradation (26,
40). In particular, ACKR2, previously known as D6, internal-
izes and degrades CC inflammatory chemokines recognized by
CCR1 to CCR5 in a competitive manner (35), thus acting as a
chemokine scavenger (10, 26). The predominant sites of
ACKR2 expression are placenta (27), lymphatic endothelial
cells (34), and some leukocyte subsets (28), where it acts as a
negative regulator of immune responses. Most studies show
that ACKR2-deficient mice (ACKR2/) present exaggerated
inflammatory responses in skin (15), placenta (27), and lungs
(7), but the role of ACKR2 remains unexplored in the context
of fibrosis. Here, we studied ACKR2 expression in lungs and
* M. Locati and M. M. Teixeira contributed equally to this work.
Address for reprint requests and other correspondence: R. C. Russo, Lab. of
Pulmonary Immunology and Mechanics, Dept. of Physiology and Biophysics,
Inst. of Biological Sciences, Univ. Federal de Minas Gerais, Avenida Antonio
Carlos, 6627, Pampulha, 31270-901, Belo Horizonte, MG, Brasil (e-mail:
remo@ufmg.br).
Am J Physiol Lung Cell Mol Physiol 314: L1010–L1025, 2018.
First published February 22, 2018; doi:10.1152/ajplung.00233.2017.
1040-0605/18 Copyright © 2018 the American Physiological Society http://www.ajplung.orgL1010
Downloaded from journals.physiology.org/journal/ajplung (090.147.182.065) on June 3, 2020.
whether it contributed to the pathogenesis of pulmonary fibro-
sis using a murine model of pulmonary fibrosis induced by
bleomycin. Our results show that pulmonary injury and inflam-
mation are reduced in the absence of ACKR2, so that pulmo-
nary function was greatly improved and survival due to in-
creased IFN-producing T-cell influx correlating to reduced
Th17 and fibrogenic response induced by bleomycin in mice.
These data reveal a previously unappreciated role of receptor
ACKR2 in the development of pulmonary fibrosis by fine
tuning chemokine-mediated migration of IFN-producing T
cells and immune regulatory function in the lungs.
MATERIAL AND METHODS
Animals. Wild-type (WT) C57BL/6j mice were purchased from
Jackson Laboratory (L’Arbresle Cedex, France). ACKR2-deficient
(ACKR2/) mice were generated as previously described (15).
CCR2/, CCR4/, and CCR5/ mice were obtained from Labo-
ratório de Imunofarmacologia/Universidade Federal de Minas Gerais
facility. Animals were maintained in a controlled environment under
pathogen-free conditions with filtered water and food ad libitum.
Bone marrow chimeras. Recipient mice were irradiated, and bone
marrow cells from donor mice (4 106 per mouse) were injected into
each recipient mouse through the retro-orbital venous plexus, as
previously described (53). Mice were challenged with bleomycin 4 wk
after bone marrow transfer.
Bleomycin-induced lung injury and fibrosis in mice. Eight to
10-wk-old male WT and ACKR2/ mice were used in bleomycin-
induced lung injury and fibrosis model performed as previously
described (38, 39, 41). Briefly, a single 40-l injection containing
3.75 mg of bleomycin sulfate (Blenoxane; Bristol-Meyers Squibb) per
kg of mice body weight diluted in PBS or PBS only (vehicle) was
instilled intranasally. All experiments were conducted conformed to
institutional guidelines in agreement with national and international
law approved by the ethics committee of the Istituto Clinico Humani-
tas and by the Brazilian animal ethics committee Comitê de Ética em
Experimentação Animal/Universidade Federal de Minas Gerais (Pro-
tocol No. 232/2012).
Soluble collagen assay. The total content of lung collagen was
measured by the Sircol soluble collagen assay (Biocolor), following
the manufacturer’s instructions.
Lung histopathology. The left lung was removed and fixed in 4%
neutral phosphate-buffered formalin (pH 7.4) and stained with hemo-
toxylin and eosin or Gomori’s trichrome, as described previously (39).
Images of lung sections were captured with a digital camera (Optron-
ics DEI-470) connected to a microscope (Olympus IX70) with a
magnification of40 or 100. Bars  100 mm for Gomori’s trichrome
and 200 mm for hemotoxylin and eosin.
Assessment of respiratory mechanic dysfunction. Mice were tra-
cheostomized, placed in a body plethysmograph, and connected to a
computer-controlled ventilator (Forced Pulmonary Maneuver System;
Buxco Research Systems, Wilmington, NC), as previously described
(36, 52). Under mechanical respiration the dynamic compliance and
lung resistance were determined by resistance and compliance test. To
measure functional residual capacity (FRC), ventilation was stopped
at the end of expiration and spontaneous breathing maneuvers with
consequent pressure changes were recorded to calculate the FRC by
Boyle’s law. To measure the chord compliance and inspiratory ca-
pacity (IC), the quasistatic pressure-volume maneuver was performed,
which inflates the lungs to a standard pressure of 30 cmH2O and
then slowly exhales until a negative pressure of 30 cmH2O is
reached. Chord compliance was determined at the pressure 10
cmH2O. The total lung capacity was calculated by FRC  IC.
Fast-flow volume maneuver was performed, and lungs were first
inflated to 30 cmH2O and immediately afterwards connected to a
highly negative pressure to enforce expiration until 30 cmH2O. The
forced vital capacity, forced expiratory volume at 50 and 100 ms, and
flow-volume curve were recorded during this maneuver. Suboptimal
maneuvers were rejected and for each test in every single mouse at
least three acceptable maneuvers were conducted to obtain a reliable
mean for all numeric parameters.
RNA isolation and real-time RT-PCR. Total lung RNA was ex-
tracted from whole lungs with TRIzol (Invitrogen) according to the
manufacturer’s instructions in a gentleMACS Dissociator (MACS;
Miltenyi Biotec). First-strand cDNA synthesis (High Capacity cDNA
Reverse Transcription Kit; Applied Biosystems) from 2 mg of total
RNA was conducted according to the manufacturer’s instructions. A
Chromo4 Real-Time PCR Detector (MJ Research) was used for
quantitative real-time PCR on cDNA (200 ng) using TaqMan Uni-
versal PCR Master Mix (Applied Biosystems) (Table 1). Results
represent the relative abundance (expressed as 2	CT) of mRNA
transcript over the total amount of 18S.
Assessment of leukocytes in airways and lungs. Bronchoalveolar
lavage (BAL) was performed to obtain leukocytes from alveolar space
as previously described (38, 39, 41). Differential counts were obtained
from cytospin evaluating the percentage leukocyte populations stained
with May-Grünwald-Giemsa and FACS analysis. Lung fragments
were incubated for 45 min in RPMI containing 100 U/ml collagenase
type IV (Sigma-Aldrich) and subsequently passed in Cell Strainer
(B&D) to obtain a single cell suspension. CD45 leukocytes from
lung parenchyma were isolated by positive selection using CD45
magnetic microbeads (Miltenyi Biotec) and MS columns, according to
the manufacturer’s instructions. Leukocytes recovered from BAL and
CD45 cells (1  106 cells) from lung parenchyma were stained with
fluorochrome-conjugated monoclonal antibodies anti-CD3, -CD4,
-CD8, -Ly6G, -Ly6C, -CD11b, -CD11c, -CD115, -MHCII, -DX5,
-TCR, -CXCR2, -CCR2, -CCR3, -CCR4, -CCR5, -RORT, -IL-
17A, and -IFN- or isotype controls (BD Pharmigen). Stained cells
were acquired in a FACSCanto cytometer (BD Biosciences) and
analyzed in BD FACSDiva software (BD Biosciences). The popula-
tions of leukocyte and phenotypes were calculated by expression of
surface or intracellular markers: neutrophils (Ly6GCXCR2), eo-
sinophils (Ly6GCCR3), macrophages (Ly6CCD115CD11b),
T lymphocytes (CD3CD4 and CD3CD8), myeloid dendritic
cells (MHCIICD11bCD11c), natural killer cells (CD3DX5),
T cells (CD3TCR), and T cell-IFN producers
(CD3TCRIFN), expressing the chemokine receptors CCR2,
CCR4, or CCR5 and Th17 lymphocytes (CD3CD4RORTIL-
17A).
Table 1. Murine-specific primers for TaqMan gene
expression assay
Name of Target Abbreviation TaqMan
18S 18S Hs99999901_s1
Bleomycin hydrolase Blmh Mm00724431_m1
Atypical chemokine receptor 2 ACKR2 Mm00445551_m1
Matrix metalloproteinase 3* MMP3 Hs00233962_m1
Matrix metalloproteinase 9 MMP9 Mm00600163_m1
Tissue inhibitor of matrix
metalloproteinase 1 TIMP-1 Mm00441818_m1
von Willebrand factor vWF Mm00550379_m1

-Smooth muscle actin 
-SMA Mm01546133_m1
Transforming growth factor-1 TGF1 Mm03024053_m1
Interleukin-17A IL-17A Mm00439619_m1
Interleukin-22 IL-22 Mm00444241_m1
Interleukin-23 IL-23 Mm00518984_m1
Interleukin-25 IL-25 Mm00499822_m1
Forkhead box P3 Foxp3 Mm00475165_m1
RAR-related orphan receptor- RORT Mm00441139_m1
Suppressor of cytokine signaling 1 SOCS1 Mm00782550_s1
Suppressor of cytokine signaling 3 SOCS3 Mm00545913_s1
SMAD family member 3 SMAD3 Mm00489638_m1
C-X-C motif chemokine 10 CXCL10 Mm00445235_m1
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Cytokine measurement in lungs. One hundred milligrams of lung
tissue were homogenized in 1 ml of PBS with protease inhibitors
(Complete tablets, Roche Diagnostic; PMSF, Sigma-Aldrich) and
0.05% Tween 20. Cytokines and chemokines were analyzed simulta-
neously using a Luminex multiplex bead assay (Bio-Rad) mouse
12-plex multicytokine (CCL2, CCL3, CCL4, CCL5, CCL11, CXCL2,
CXCL9, IL-1, IL-6, IL-10, TNF-
, and VEGF) beads in accord-
ing to the manufacturer’s instructions. The chemokines CCL12,
CCL17, CCL22, and cytokines IL-13, active transforming growth
factor-1 (TGF-1), and IFN levels were quantified using DuoSet
ELISA kits (R&D Systems), in accordance with the manufacturer’s
instructions (39).
T-lymphocyte depletion in vivo. T lymphocytes were depleted
in WT and ACKR2/ mice by intraperitoneal injection with 250
g/day of purified hamster anti-TCR (clone UC7-13D5; BD
PharMingen) or IgG isotype control (BD PharMingen) in sterile PBS,
as previously described (3, 19), at days 2 and 0 before bleomycin
instillation (3.75 mg/kg).
Statistical analysis. All data are presented as the means  SE and
were analyzed by one-way ANOVA and differences between groups
were assessed using the Student-Newman-Keuls post hoc test or
log-rank test. Graphs and analysis were performed using GraphPad
Prism 4 software. Differences were considered significant at P 0.05.
RESULTS
ACKR2 deficiency protects against bleomycin-induced pul-
monary fibrosis and dysfunction. In the lung tissue of animals
instilled with bleomycin, we observed an acute upregulation of
ACKR2 transcripts, which peaked at day 2 and then decreased
over time returning to basal values in the chronic phase (at day
16) (Fig. 1A). As ACKR2 transcript upregulation preceded the
development of pulmonary fibrosis, we investigated its role in
this experimental setting comparing WT and ACKR2/ mice
instilled with bleomycin. As compared with WT animals,
ACKR2/ mice showed decreased lethality rate (Fig. 1B) and
body weight loss (Fig. 1C). Consistent with this, the increase in
lung collagen content observed in WT animals instilled with
bleomycin was significantly reduced in ACKR2/ mice (Fig.
1D). Semiquantitative analyses of lung tissue sections (Figs. 1,
E–H) revealed dense and diffuse interstitial lung fibrosis with
loss of pulmonary architecture in WT mice (Fig. 1G), while
ACKR2/ mice showed less pronounced fibrosis and pre-
served areas of lung parenchyma (Fig. 1H). In this experimen-
tal setting, pulmonary dysfunction was evident both at days 8
and 22 after bleomycin instillation and was demonstrated by
reduction of lung volumes and airway flow, with marked
reduction of total lung capacity and forced vital capacity and
progressive loss of IC and forced expiratory volume (Fig. 2A).
There was also progressive (from days 8 to 22) reduction of
lung elasticity, as seen by progressive reduction in pulmonary
compliance and gain of lung resistance in WT mice with
bleomycin (Fig. 2A). Overall, all these mechanic functional
changes were less intense in ACKR2/ mice (Fig. 2, A and
B). Indeed, there was reduced airway flow (Fig. 2B) and
flattened pressure  volume curve (Fig. 2C), characteristic of
pulmonary fibrosis, 22 days after bleomycin in WT mice but
not in ACKR2/ mice. Collectively, evidence indicates that
ACKR2/ mice are significantly protected from bleomycin-
induced lung injury and consequent pulmonary dysfunction,
suggesting a nonredundant role of ACKR2 in the pathogenesis
of pulmonary fibrosis.
ACKR2 deficiency reduces lung injury and leukocyte influx
induced by bleomycin. To characterize the protective effect of
ACKR2 deletion on bleomicyn-induced lung fibrosis, we first
analyzed lungs of WT and ACKR2/ mice exposed to bleo-
mycin. While at early time points (days 2 and 4) there was no
evidence of tissue damage in any genetic background, we
found an early gain of lung resistance in WT but not in
ACKR2/ mice 2 days after bleomycin instillation (Table 2).
At day 8, WT mice showed multiple inflammatory foci in the
lung parenchyma, which developed into extensive areas of
inflammation at later time points (~75 and 90% of slices area
at days 12 and 16, respectively) with loss of pulmonary
architecture (Fig. 3A). Inflammatory foci at day 8 were signif-
icantly reduced in lungs of ACKR2/ mice, which showed a
relatively well-preserved pulmonary architecture at later time
points (~35% and 50% of area at days 12 and 16, respectively)
(Fig. 3A). Consistent with lung tissue damage, bleomycin
induced progressive recruitment of leukocyte into the airways
of WT mice, with early increase in neutrophils and chronic
infiltration of eosinophils, lymphocytes, and monocyte/macro-
phages (Fig. 3B). Similarly, when total lung leukocytes were
recovered by CD45 immunomagnetic sorting from collage-
nase-digested lungs and leukocyte subsets evaluated by FACS
analysis, a significant accumulation of neutrophils, eosinophils,
macrophages, T lymphocytes, and myeloid dendritic cells in
the lung tissue of WT animals instilled with bleomycin was
observed (Fig. 3C). Consistent with the protective effect of
ACKR2 deletion reported in Fig. 1, in both compartments leu-
kocyte accumulation was significantly reduced in ACKR2/ mice
(Fig. 3, B and C). Thus, in the absence of ACKR2, bleomycin-
induced pulmonary inflammation and fibrosis are greatly re-
duced.
ACKR2-deficient mice show a distinct profile of cytokines
and chemokines. As expected, bleomycin instillation was
associated with increased levels of proinflammatory and
fibrogenic cytokines, such as IL-1, IL-6, IL-13, and active
TGF-1, in lungs of WT mice, all of which were reduced in
ACKR2/ mice (Fig. 4A). On the contrary, bleomycin
induced an early increase (day 2) of IFN selectively in the
lungs of ACKR2/ mice (Fig. 4A). Instillation of bleomy-
cin also led to increased levels of several CC and CXC
chemokines (Fig. 4B). As compared with WT animals,
ACKR2/ mice had increased pulmonary levels of CCL5,
CCL12, and CCL17 at day 2 after bleomycin instillation,
while the levels of CCL2, CCL3, CCL11, CXCL2, and
CXCL9 were reduced (Fig. 4B).
ACKR2 deficiency impacts on the fibrogenic transcriptional
program. As WT and ACKR2/ mice expressed similar
levels of bleomycin hydrolase (data not shown), we next
evaluated whether the absence of ACKR2 affected pulmonary
expression of genes associated with fibrogenesis, including
tissue remodeling markers and Th17-associated genes. In WT
mice, bleomycin induced expression of tissue remodeling
genes (matrix metalloproteinase-3 and -9/tissue inhibitor of
metalloproteinase-1, von Willebrand factor, and 
-smooth
muscle actin; Fig. 5A), increased expression of profibrogenic
Th17-associated genes (IL-17A, IL-22, IL-23, IL-25, and reti-
noic acid receptor-related orphan receptor; Fig. 5, B and C),
and upregulated Treg-associated genes (FoxP3, TGF-1, and
SMAD family member 3; Fig. 5C). There was also enhanced
expression of genes associated with negative regulation of Th1
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responses (SOCS1 and SOCS3; Fig. 5C). Overall, the expres-
sion of these genes was significantly reduced in ACKR2/
mice exposed to bleomycin (Fig. 5, A–C).
Lung parenchyma ACKR2 expression contributes to pulmo-
nary fibrosis. To investigate the relative contribution of
ACKR2 expression on lymphatic endothelial cells or leuko-
cytes on the protection observed in ACKR2/ mice exposed
to bleomycin, bone marrow chimera experiments were per-
formed (53). Lethality rate (Fig. 6A), weight loss (Fig. 6B), and
total lung collagen (Fig. 6C) were similar in WT (Fig. 1) and
in chimeric WT¡WT and ACKR2/¡WT mice exposed to
bleomycin, while all parameters were decreased in ACKR2/
Fig. 1. Expression of ACKR2 in lungs: receptor upregulation in lungs and pulmonary ACKR2 deficiency protects against lethality and pulmonary fibrosis. Mice received
a single instillation with PBS or bleomycin (3.75 mg/kg body wt). A: kinetic of lung ACKR2 receptor mRNA expression in wild-type (WT) mice by real-time PCR using
Taqman probes after PBS () or bleomycin instillation (). B and C: results represent the relative abundance (expressed as 2	CT) of mRNA transcript over the total
amount of 18S. WT () and ACKR2/ mice (Œ) lethality (B) and weight loss (C) were monitored daily after bleomycin instillation. D–H: after 22 days of bleomycin
instillation WT and ACKR2/ mice were culled for fibrosis assessment by total lung collagen quantification by Sircol assay (D) and lung histopathology assessment
by representative photomicrography of Gomori’s Trichrome staining (E–H). Bars 100 m at100 magnification. E and F: PBS-instilled WT mice (E) or ACKR2/
(F) mice presented normal lung architecture. G and H: histopathology shows a dense and diffuse interstitial lung fibrosis with loss of pulmonary architecture in WT mice
(G) bleomycin-challenged mice, whereas there was a focal and less pronounced fibrosis with preserved areas of lung parenchyma in ACKR2/ mice (H). Results are
shown as the means SE of 13–16 animals in each group. *P  0.05 and **P  0.01 and ***P  0.001, when comparing WT-given bleomycin-challenged mice to
instilled-ACKR2/ mice. Repeated experiments generated similar data sets.
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(Fig. 1) and in chimeric WT¡ACKR2/ and ACKR2/
¡ACKR2/ mice exposed to bleomycin (Figs. 6, A–C).
Similarly, histopathological analysis confirmed diffuse and
dense interstitial lung fibrosis in WT¡WT (Fig. 6F) and
ACKR2/¡WT mice (Fig. 6H), while WT¡ACKR2/
(Fig. 6G) and ACKR2/¡ACKR2/ mice (Fig. 6I) had
reduced lung fibrosis when exposed to bleomycin. We con-
clude that the protective phenotype observed in ACKR2/
animals is associated to the expression of ACKR2 by nonhe-
matopoietic (parenchyma) cells.
ACKR2 deficiency results in increased recruitment of
CCR2 and CCR5 IFN-producing T cells. In WT ani-
mals, ACKR2 transcripts peaked at the 2-day time point after
Fig. 2. ACKR2 deficiency protects mice from pulmonary mechanic dysfunction induced by bleomycin. Mice received a single instillation with PBS or bleomycin
(3.75 mg/kg body wt) and the pulmonary mechanics assessed by Buxco Pulmonary Function Tests using forced spirometry at days 8 and 22. A: modification
in lung volumes: total lung capacity (TLC), forced vital capacity (FVC), and inspiratory capacity (IC); airway flow: forced expiratory capacity at 50 and 100
ms (FEV50 and FEV100); and pulmonary elasticity: dynamic and chord compliance, and lung resistance were induced by bleomycin in inflammatory phase (day
8) and fibrogenic phase (day 22). B and C: during the fibrogenic phase, at day 22 postbleomycin, the flow  volume (B) and pressure  volume (C) curves were
evaluated by spirometry. Bleomycin-instilled wild type (WT) mice (filled squares) or ACKR2/ mice (gray circles) with respective controls, PBS-treated WT
(black circles), and ACKR2/ mice (open triangles). Results are shown as the means  SE of 5–8 animals in each group. *P  0.05 and **P  0.01, when
comparing WT or ACKR2/ instilled mice with respective PBS-treated controls; #P  0.05, when comparing WT-given bleomycin-challenged mice with
bleomycin-instilled ACKR2/ mice.
Table 2. Pulmonary resistance in bleomycin-induced acute
lung injury day 2
Groups Means  SE P Value
WT PBS 0.72  0.039
ACKR2 PBS 0.76  0.056
WT bleomycin 1.25  0.090 P  0.01, WT PBS vs. WT BLEO
ACKR2 bleomycin 0.94  0.033 P  0.01, ACKR2 BLEO vs.
WT BLEO
WT, wild type; BLEO, bleomycin.
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bleomycin instillation, the same time point when the well-
known antifibrogenic cytokine IFN (58) was also shown to
peak selectively in ACKR2/ animals (compare Figs. 1A and
4). Consistent with this, FACS analyses at 2 days after bleo-
mycin showed a similar profile of accumulation of neutrophils,
eosinophils, macrophages, T lymphocytes, myeloid dendritic
cells, and natrual killer cells in lung tissue and airways of WT
and ACKR2/ mice (Fig. 7A) but a significant increase in the
number of IFN T cells retrieved from lungs and airways
of ACKR2/ mice (Fig. 7, A and B). Finally, when T cells
were further investigated for the expression of CC chemokine
receptors, ACKR2/ mice showed a significant increase in
the number of CCR2 and CCR5 T lymphocytes mostly
IFN, as compared with WT mice, while no difference in
Fig. 3. ACKR2 deficiency reduces leukocyte influx and lung injury induced by bleomycin. A: mice received a single instillation with PBS or bleomycin (3.75
mg/kg of body wt), and pulmonary pathology was assessed using hematoxilin & eosin staining at days 2, 4, 8, 12, and 16 after bleomycin challenge. Areas of
tissue injury and inflammation induced by bleomycin are indicated in wild-type (WT) mice (arrows) and ACKR2/ mice (arrowhead). Bars  200 m at 40
magnification. B: leukocyte influx into the airway space was quantified using Neubauer chamber and cytospin preparations. BAL, bronchoalveolar lavage. C:
lung leukocyte were recovered from lung parenchyma by CD45 selection using magnetic beads and stained for FACS analysis: neutrophils (Ly6GCXCR2),
eosinophils (Ly6GCCR3), macrophages (Ly6CCD115CD11b), T-lymphocytes (CD3CD4 and CD3CD8), and myeloid dendritic cells
(MHCIICD11bCD11c). Results are shown as the means  SE of 5–8 animals in each group. *P  0.05 and **P  0.01, comparing WT-given
bleomycin-challenged mice () to instilled-ACKR2/ mice (Œ).
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CCR4 T lymphocytes was observed (Fig. 7B). We then
used specific gene-targeted mice to identify the CC chemokine
receptor responsible for the increased influx of IFN T
cells observed in ACKR2-deficient animals exposed to bleo-
mycin. Although CCR2/, CCR4/, and CCR5/ mice
showed a number of total lymphocytes recruited after bleomy-
cin challenge comparable to WT mice (data not shown), in
CCR2/ and CCR5/, but not CCR4/, mice there was a
significant decrease in total number of T cells (Fig. 8A) and
IFN T cells (Fig. 8B). Interestingly, CCR2/ mice
showed reduced CCR5 IFN T cells and CCR5/ mice
exhibited reduced CCR2 IFN T cells (Fig. 8B). Despite
the increased acute accumulation of T and IFN T cells
in ACKR2/ mice compared with WT mice at day 2 (Figs. 7B
and 9A) and day 4 (Fig. 9A) after bleomycin instillation, we
observed that it was not restricted to acute phase but was
progressively increased in chronic time points (days 8 and 12)
postbleomycin (Fig. 9A). In addition, there was a mixed IFN
T cell population expressing CCR2 and CCR5 in airways
(days 2 and 4) (Fig. 9, B and C), with the predominance of
CCR2 IFN T cells in chronic periods (Fig. 9B) in
ACKR2/ mice (Fig. 9C) challenged with bleomycin. Re-
cently, Segawa et al. (43) demonstrated that IFN T cells
suppresses Th17 activity in bleomycin model. Thus we eval-
uated the kinetic of Th17 lymphocyte influx in airways. We
found decreased numbers of Th17 lymphocytes in ACKR2/
mice compared with WT mice (Fig. 9D), as confirmed by
mRNA expression (Fig. 5, B and C). We conclude that after
bleomycin instillation the inflammatory CC chemokine recep-
tors control the recruitment of IFN T cells in the airways
and the impact of ACKR2 absence is associated with a signif-
icant increase of CCR2 and CCR5 IFN T cells and
related to downregulation of the Th17 lymphocytes.
Depletion of T cells reverses the protection observed in
the absence of ACKR2. To test whether T cells contributed
to the protection observed in ACKR2/ mice exposed to
bleomycin, WT and ACKR2/ mice were treated with a
TCR-depleting antibody or its isotype control. Isotype-
Fig. 4. ACKR2-deficient mice show a distinct profile of chemokines and cytokines after bleomycin challenge. A and B: mice received a single instillation with
PBS or bleomycin (3.75 mg/kg body wt) and the kinetic of pulmonary levels of cytokines IL-1, IL-6, IL-13, active transforming growth factor-1 (TGF-1),
and IFN- (A) and chemokines CCL2, CCL3, CCL4, CCL5, CCL11, CCL12, CCL17, CCL22, CXCL2, and CXCL9 (B) were evaluated by Luminex/Bio-Plex
or ELISA. Results are shown as the means  SE of 5–8 animals in each group. *P  0.05 and **P  0.01, comparing wild-type (WT)-given
bleomycin-challenged mice () to instilled-ACKR2/ mice (Œ).
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treated ACKR2/ mice remained significantly healthier than
isotype-treated WT mice when challenged with bleomycin
(Fig. 10, A–C). ACKR2/ and WT mice treated with deplet-
ing anti-TCR antibodies exhibited greater lethality (Fig.
10A) and weight loss (Fig. 10B) and increased lung fibrosis
(Fig. 10C), as compared with the isotype control groups. A
dense and diffuse interstitial lung fibrosis with loss of pulmo-
nary architecture was observed in isotype-treated WT mice
exposed to bleomycin (Fig. 10F). Histopathological changes
were more severe in WT mice treated with anti-TCR (Fig.
10H). In isotype-treated ACKR2/ mice, bleomycin caused
focal and less-pronounced fibrosis with preserved areas of lung
parenchyma (Fig. 10G), but T-cell-depleted ACKR2/
mice displayed diffuse interstitial lung fibrosis (Fig. 10I) sim-
ilar to WT mice (Fig. 10F). Taken together, evidence indicates
that T lymphocytes recruited in the airways after bleomycin
instillation are responsible for the resistance to the bleomycin-
induced pulmonary fibrosis observed in ACKR2/ mice.
DISCUSSION
Although fibrogenesis is clearly associated to increased
expression of chemokines (45, 58), the role in lung fibrosis of
ACKR2, a scavenger receptor for most inflammatory CC
chemokines, has not been previously addressed. ACKR2 is an
essential regulatory molecule for inflammatory responses in
vivo, as ACKR2/ mice display enhanced inflammation (5, 7,
10, 15, 56), tumor development (33, 53), and fetal loss (27).
However, in other experimental settings, such as colitis (3),
spinal cord inflammation and demyelination models (24), and
bone remodeling (23), ACKR2 has been associated with a
protective effect. Here, we first described the involvement of
ACKR2 in pulmonary fibrosis and report experimental evi-
dence indicating that pulmonary fibrosis and dysfunction are
attenuated in ACKR2/ mice. Our data can be summarized as
the following explains. First, there was acute, but not chronic,
upregulation of lung ACKR2 mRNA after bleomycin instilla-
Fig. 5. ACKR2 deficiency protects from the fibrogenic transcriptional program induced by bleomycin. Mice received a single instillation with PBS or bleomycin
(3.75 mg/kg body wt) and levels of total lung mRNA expression of profibrogenic related genes were monitored using quantitative real time PCR at days 2, 4,
8, 12, and 16 after bleomycin instillation. A: tissue remodeling markers: matrix metalloproteinase-3 and -9 (MMP3 and MMP9), tissue inhibitor of
metalloproteinase-1 (TIMP-1), von Willebrand factor (vWF), and 
-smooth muscle actin (
 -SMA). B: Th17 fibrogenic cytokines: IL-17A, IL-22, IL-23, IL-25,
and transforming growth factor-1 (TGF-1). C: fibrogenic and Th17-related transcription factors: retinoic acid receptor-related orphan receptor T (RORT),
forkhead box-P3 (FoxP3), suppressor of cytokine signaling-1 and -3 (SOCS1 and SOCS3), and SMAD family member 3 (SMAD3) were targeted in lungs of
wild-type (WT) and ACKR2/ mice. Results represent the relative abundance (expressed as 2	CT) of mRNA transcript over the total amount of 18S. Results
are shown as the means  SE of 5–8 animals in each group. *P  0.05 and **P  0.01, when comparing WT-given bleomycin-challenged mice () to
instilled-ACKR2/ mice (Œ).
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Fig. 6. Lethality and pulmonary fibrosis induced by bleomycin is dependent of ACKR2 expression by nonhematopoietic (lung parenchyma) cells. A and B:
lethality (A) and weight loss (B) from chimerical bone marrow constructs wild-type (WT) BMdo¡WT BMre (□), WT BMdo¡ACKR2/ BMre (),
ACKR2/ BMdo¡WT BMre (), and ACKR2/ BMdo¡ACKR2/ BMre (Œ) were monitored daily after bleomycin instillation (3.75 mg/kg of body wt).
BMdo, bone-marrow donor; BMre, bone-marrow recipient mice. C–I: after 21 days of bleomycin instillation the chimerical bone marrow constructs were culled
for fibrosis assessment by total lung collagen quantification by Sircol assay (C) and lung histopathology assessment, by representative photomicrography of
Gomori’s Trichrome staining (D–I). Bars  100 m at 100 magnification. D and E: PBS-instilled WT mice (D) or ACKR2/ (E) mice presented normal
lung architecture. F–H: histopathology shows a dense and diffuse interstitial lung fibrosis with loss of pulmonary architecture in WT BMdo¡WT BMre (F) and
ACKR2/ BMdo¡WT BMre (H) bleomycin-challenged mice, whereas there was a focal and less pronounced fibrosis with preserved areas of lung parenchyma
in ACKR2/ BMdo¡ACKR2/ BMre (G) and WT BMdo¡ACKR2/ BMre (I). Results are shown as the means  SE of 13–16 animals in each group.
*P  0.05 and **P  0.01 and ***P  0.001, when comparing WT-given bleomycin-challenged mice to instilled-ACKR2/ mice. Repeated experiments
generated similar data sets.
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tion in WT mice. Second, ACKR2/ mice were protected
from lethality, pulmonary inflammation, tissue remodeling,
and dysfunction induced by bleomycin. Third, expression of
ACKR2 in lung paremchyma cells accounted for the phenotype
observed. Fourth, there was early increased IFN- expression,
mostly by CCR2 and CCR5 T cells in ACKR2/ mice
exposed to bleomycin. Expression of these cells coincided with
increase in the concentration of chemokines active to CCR2
and CCR5. Fifth, accumulation of IFN T cells was
impaired in CCR2/ and CCR5/ mice. Sixth, there was
progressive accumulation of CCR2 and CCR5 IFN-pro-
ducing T cells and reduced Th17 response in airways from
ACKR2/ mice exposed to bleomycin. Seventh, T-cell
depletion was able to prevent the protection conferred by
ACKR2 deficiency. Therefore, ACKR2 controls the early pro-
duction of CCR2- and CCR5-active chemokines that drive the
influx of IFN-producing T cells, which exert an important
control of the fibrogenic response to bleomycin.
ACKR2 binds and scavenges multiple CC chemokines and
attenuates lung inflammation induced by Mycobacterium tu-
berculosis infection and allergen challenge in mice (7, 56). In
chronic obstructive pulmonary disorder and sepsis patients,
ACKR2 is mostly expressed by alveolar macrophages, also
expressed by lung lymphatics from smokers (2, 5, 31). We
were not able to identify which cell of the parenchyma ex-
presses the ACKR2 receptor because of the limitation of tools
to detect murine ACKR2 available in the market. Using bone-
marrow chimeras, we found that ACKR2 expression in paren-
chyma cells was relevant for induction of pulmonary fibrosis in
mice. It is possible that ACKR2 can be expressed by alveolar
macrophages or lymphatic endothelium. Indeed, the develop-
ment of lung fibrosis is believed to be associated with leuko-
Fig. 7. Increased recruitment of CCR2 and
CCR5, but not CCR4, IFN--producing
T cells after bleomycin instillation in the
absence of ACKR2. A: mice received a sin-
gle instillation with PBS or bleomycin (3.75
mg/kg of body wt), and 2 days after lung
leukocytes were recovered from lung paren-
chyma by CD45 selection using magne-
tic beads, stained for neutrophils (Ly6G
CXCR2), eosinophils (Ly6GCCR3), mac-
rophages (Ly6CCD115CD11b), T-lympho-
cytes (CD3CD4 and CD3CD8), myeloid
dendritic cells (MHCIICD11bCD11c), nat-
ural killer (NK) cells (CD3DX5), and T
cell (CD3TCR) analyzed by FACS. B: the
phenotype of T cells recovered in airway
space was analyzed by FACS and evaluated by
expression of CCR2, CCR4 and CCR5 re-
lated to respective populations of CD3TCR
lymphocytes and CD3TCRIFN- for
IFN--producer T-lymphocytes. BAL, bron-
choalveolar lavage. Results are shown as the
means SE of 5–8 animals in each group. *P
0.05 and **P  0.01, when comparing WT-
given bleomycin-challenged mice to instilled-
ACKR2/ mice.
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cyte infiltration and tissue injury that precedes the aberrant
remodeling (16, 60). The reduced lung injury associated to
impaired leukocyte influx could account for the protection of
ACKR2/ mice. Furthermore, based on our data, and as
previously shown (5, 7, 56), the impact of ACKR2 deficiency
on progression of pulmonary inflammation and injury is de-
pendent on the precise nature of the challenge.
Pulmonary fibrogenesis is characterized by increased paren-
chyma remodeling (8, 58) and is critically regulated by chemo-
kines (47, 48, 51, 58) and Th2/Th17 responses (58). We found
that ACKR2/ mice displayed decreased pulmonary fibrosis
and dysfunction and these were related to reduced expression
of mRNA transcripts of genes associated with fibrogenesis (39,
41, 50, 59) and Th2/Th17 responses, mostly by reduction in
Th17 numbers in airways. IFN is a cytokine with antifibrotic
proprieties and a negative regulator of TGF-1 action in the
context of pulmonary fibrosis (22). IFN was elevated early in
ACKR2/ mice but not in WT mice after bleomycin. This
early elevation may account for the reduced fibrogenesis and
production of fibrogenic factors, including IL-1 (57), IL-6
(42), IL-13 (9), active TGF-1 (9), CCL2 (11, 30, 61), CCL3
(14, 38, 49), and CXCL2 (18, 41). These results suggest that
ACKR2 tunes the lung fibrogenesis through modulation of a
fibrogenic program. Moreover, ACKR2/ mice had low lev-
els of lung IL-13, TGF-1 and Th17 activity after bleomycin
and these are known to act synergistically to induce lung
fibrogenesis (29, 43, 57), suggesting that IFN activity could
block the fibrogenesis dampening the TGF-1 and Th17 re-
sponse in ACKR2/ mice.
We found that ACKR2 deficiency resulted in elevated levels
of CCL5, CCL12, and CCL17 at the same time that ACKR2
expression peaked in WT mice. These chemokines act on
CCR5, CCR2, and CCR4, respectively, and hence induce
recruitment of T after bleomycin challenge. Therefore,
ACKR2 deficiency in lungs could modify the local chemokine
microenvironment, supporting T-cell influx. In fact, CCR2
and CCR5 T cells were elevated in ACKR2/ mice and
correlated with the elevation of pulmonary levels of CCL5,
CCL12, and IFN. T cells can exhibit polarized phenotypes,
which reflects on the pattern of chemokine receptor expression
(17). Th1 T cells express CXCR3 and CCR5, whereas
CCR4 is expressed by Th2 T cells (17). In addition, Th1
CCR2 T cells are potent IFN- producers and displayed
cytotoxic functions in tumor beds (21). In keeping with this,
there was an increase in Th1 IFN-producing CCR2 and
CCR5 T cells in ACKR2/ mice challenged with bleo-
mycin. In response to bleomycin, there was also an impaired
recruitment of IFN T cells in CCR2/ and CCR5/ but
not CCR4/ mice. Interestingly, CCR2/ mice showed
reduced CCR5 IFN T cells and CCR5/ mice exhib-
ited reduced CCR2 IFN T cells. Altogether, these data
indicate that in absence of ACKR2 increased levels of CCL12
and CCL5 observed after bleomycin challenge may be respon-
sible for the recruitment of CCR2 and CCR5 IFN T
cells which protect the mice.
Recent observations elucidated the ability of T cells to
produce cytokines that regulate homeostasis and tissue stress
(6). T cells occur in healthy lungs (55), and their number is
Fig. 8. CCR2 and CCR5, but not CCR4, deficiency impacts the IFN--producing T-cell recruitment after bleomycin instillation. Mice received a single
instillation with PBS or bleomycin (3.75 mg/kg body wt) and 2 days after, leukocytes recovered from airway space of CCR2/, CCR4/, and CCR5/ mice
were analyzed by FACS. A and B: the phenotype of T cells recovered in airway space was evaluated by expression of CCR2, CCR4, and CCR5 (A) and
CD3TCRIFN- for INF--producer T-lymphocytes (B). BAL, bronchoalveolar lavage. Results are shown as the means  SE of 5–8 animals in each
group. *P  0.05 and **P  0.01, when comparing WT-given bleomycin-challenged mice to instilled-CCR2/, CCR4/, and CCR5/ mice.
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Fig. 9. Increased recruitment of CCR2 and CCR5 IFN--producing T cells is related to reduced Th17 response after bleomycin instillation in the absence
of ACKR2. Mice received a single instillation with PBS or bleomycin (3.75 mg/kg of body wt) and 2, 4, 8, and 12 days after, leukocytes recovered from airway
space of WT and ACKR2/ mice were analyzed by FACS. A–C: the phenotype of IFN--producer T lymphocytes in airway space was analyzed by FACS
(A) and evaluated by expression of CCR2 (B) and CCR5 (C) related to respective populations of CD3TCR lymphocytes and CD3TCRIFN-.
BAL, bronchoalveolar lavage. D: Th17 lymphocyte population was analyzed by FACS using (CD3CD4RORTIL-17A). Results are shown as the
means  SE of 5–8 animals in each group. *P  0.05 and **P  0.01, when comparing WT-given bleomycin-challenged mice to instilled-ACKR2/ mice.
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Fig. 10. T-lymphocyte depletion enhances lethality and pulmonary fibrosis induced by bleomycin and reverts the protection under ACKR2 deficiency. A–H:
mice received a single instillation with PBS or bleomycin (3.75 mg/kg body wt) and mouse phenotype was studied during 20 days. Wild-type (WT) and
ACKR2/ mice were injected intraperitoneally with anti-TCR (250 g/mice at days 2 and 0 preceding bleomycin instillation) or control-IgG (250 g/mice
at days 2 and 0 preceding bleomycin). A: lethality after bleomycin instillation in WT mice treated with control-IgG (), ACKR2/ mice treated with
control-IgG (Œ), WT mice treated with anti-TCR (Œ), and ACKR2/ mice treated with anti-TCR (open triangles) were monitored daily after bleomycin
instillation. B–H: after 20 days of bleomycin instillation WT and ACKR2/ mice treated with antibodies were culled for fibrosis assessment by total lung
collagen quantification by Sircol assay (B) and lung histopathology assessment, by representative photomicrography of Gomori’s trichrome staining (C–H). C
and D: bars  100 m at 100 magnification. PBS-instilled WT mice (C) or ACKR2/ mice (D) presented normal lung architecture. E–H: histopathology
shows a dense and diffuse interstitial lung fibrosis with loss of pulmonary architecture in WT mice treated with control-IgG (E), WT mice treated with
anti-TCR (G), and ACKR2/ mice treated with anti-TCR (H) challenged with bleomycin, whereas there was a focal and less pronounced fibrosis with
preserved areas of lung parenchyma in ACKR2/ mice treated with control-IgG (F). Results are shown as the means  SE of 13–16 animals in each group.
*P  0.05 and **P  0.01 and ***P  0.001, when comparing WT-given bleomycin-challenged mice to instilled-ACKR2/ mice.
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reduced in BAL and blood from IPF patients (12, 44), suggest-
ing that they play a role in pulmonary homeostasis and fibrosis.
There is evidence that T cells reduce tissue damage and
fibrosis associated with pulmonary inflammation and infection
(4, 19, 20, 32, 37, 43, 46) by mechanisms that include regula-
tion of IL-22, IL-17A (4), and CXCL10 production (37),
although we did not detect increased levels of CXCL10 (data
not shown) or IL-22 in lungs of ACKR2/ mice. Recently,
Segawa et al. (43) demonstrated the regulatory role of IFN
T cells suppressing Th17 activity in bleomycin model. In
fact, we found an increased number of CCR2 IFN T-
and CCR5 IFN T-cell influx into airways of ACKR2/
mice challenged with bleomycin, and it was related to de-
creased numbers of Th17 lymphocytes when compared with
WT mice, as confirmed by mRNA expression. Our results
show that antibody-mediated depletion of T cells worsened
bleomycin-induced lethality and fibrosis in WT and
ACKR2/ mice. It is possible that this may be due to elevated
levels of IL-17A in T-cell-depleted mice, as found in /
mice (43). Finally, the presence of IFN-producers T cells
could block pulmonary fibrosis in ACKR2/ mice through
the inhibition of Th17 expansion and fibrogenesis (4, 37, 43,
46).
In conclusion, our data demonstrate that ACKR2 is induced
during the development of pulmonary fibrosis caused by bleo-
mycin challenge and that its deletion leads to reduced lethality,
lung injury, inflammation, and fibrosis. Mechanistically,
ACKR2 is determinant for controlling the recruitment of
CCR2 and CCR5 T cells, which produce IFN and
influence subsequent development of Th17 response and in-
tensity of fibrosis.
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